Transcriptional O
activation O
of O
the O
human B
interleukin I
- I
2 I
( I
IL I
- I
2 I
) I
gene I
, O
like O
induction O
of O
the O
IL B
- I
2 I
receptor I
alpha I
( I
IL I
- I
2R I
alpha I
) I
gene I
and O
the O
type O
1 O
human O
immunodeficiency O
virus O
( O
HIV O
- O
1 O
) O
, O
is O
shown O
to O
be O
modulated O
by O
a O
kappa B
B I
- I
like I
enhancer I
element I
. O

Transcriptional O
activation O
of O
the O
human B
interleukin I
- I
2 I
( I
IL I
- I
2 I
) I
gene I
, O
like O
induction O
of O
the O
IL B
- I
2 I
receptor I
alpha I
( I
IL I
- I
2R I
alpha I
) I
gene I
and O
the O
type O
1 O
human O
immunodeficiency O
virus O
( O
HIV O
- O
1 O
) O
, O
is O
shown O
to O
be O
modulated O
by O
a O
kappa B
B I
- I
like I
enhancer I
element I
. O

Definition O
of O
T B
- I
cell I
specific I
DNA I
- I
binding I
factors I
that O
interact O
with O
a O
3 B
' I
- I
silencer I
in O
the O
CD4 B
+ I
T I
- I
cell I
gene I
Rpt I
- I
1 I
. O

Definition O
of O
T B
- I
cell I
specific I
DNA I
- I
binding I
factors I
that O
interact O
with O
a O
3 B
' I
- I
silencer I
in O
the O
CD4 B
+ I
T I
- I
cell I
gene I
Rpt I
- I
1 I
. O

Analysis O
of O
the O
region O
3 O
' O
to O
the O
CD4 B
+ I
T I
- I
cell I
gene I
Rpt I
- I
1 I
( O
encoding O
regulatory O
protein O
T B
- I
lymphocyte I
1 I
) O
led O
to O
the O
definition O
of O
a O
silencer B
element I
that O
inhibits O
heterologous B
gene I
expression O
in O
certain O
CD4 O
+ O
T O
- O
cell O
lines O
but O
not O
in O
B O
- O
cell O
or O
non O
- O
lymphoid O
cell O
lines O
. O

The O
present O
study O
demonstrates O
that O
both O
the O
ubiquitous B
and I
lymphoid I
- I
cell I
- I
specific I
octamer I
transcription I
factors I
( O
OTF B
- I
1 I
and O
OTF B
- I
2 I
, O
respectively O
) O
interact O
specifically O
with O
each O
of O
the O
two O
conserved B
sequence I
elements I
, O
forming O
either O
homo B
- I
or I
heterodimeric I
complexes I
. O

The O
octamer O
sequence O
ATGCAAAT O
is O
found O
in O
the O
promoters O
of O
immunoglobulin B
( I
Ig I
) I
heavy I
and I
light I
chain I
genes I
and O
in O
the O
heavy B
chain I
enhancer I
and O
is O
a O
major O
determinant O
of O
the O
cell O
type O
specific O
expression O
of O
Ig B
genes I
in O
B O
cells O
. O

The O
enhancer B
- I
binding I
factor I
NF I
- I
kappa I
B I
, O
which O
is O
found O
only O
in O
cells O
that O
transcribe O
immunoglobulin B
light I
chain I
genes I
, O
has O
been O
purified O
from O
nuclear O
extracts O
of O
Namalwa O
cells O
( O
human O
Burkitt O
lymphoma O
cells O
) O
by O
sequence O
- O
specific O
DNA O
affinity O
chromatography O
. O

Lymphocyte O
glucocorticoid B
receptor I
binding O
in O
depression O
: O
normal O
values O
following O
recovery O
. O

Identification O
and O
purification O
of O
a O
human B
lymphoid I
- I
specific I
octamer I
- I
binding I
protein I
( O
OTF B
- I
2 I
) O
that O
activates O
transcription O
of O
an O
immunoglobulin B
promoter I
in O
vitro O
. O

We O
report O
here O
the O
chromatographic O
separation O
of O
ubiquitous B
and I
B I
cell I
- I
specific I
octamer I
- I
binding I
proteins I
. O

This O
B B
cell I
- I
specific I
octamer I
- I
binding I
factor I
, O
in O
pure O
form O
, O
activated O
transcription O
from O
a O
kappa B
light I
chain I
promoter I
in O
vitro O
, O
thus O
demonstrating O
that O
it O
is O
indeed O
a O
B B
cell I
- I
specific I
transcription I
factor I
for O
this O
gene O
. O

In O
addition O
to O
the O
ubiquitous B
and I
B I
cell I
- I
specific I
octamer I
- I
binding I
factors I
, O
we O
identified O
several O
additional O
proteins O
, O
one O
of O
which O
is O
B O
cell O
- O
specific O
, O
that O
interact O
with O
the O
kappa B
promoter I
. O

In O
contrast O
, O
cells O
from O
a O
HTLV O
- O
1 O
transformed O
T O
lymphocyte O
line O
( O
Ab O
- O
VDR O
) O
established O
from O
a O
patient O
with O
vitamin O
D O
- O
resistant O
rickets O
type O
II O
with O
undetectable O
1 B
, I
25 I
( I
OH I
) I
2D3 I
cellular I
receptors I
are O
resistant O
to O
the O
action O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
. O

Inhibition O
of O
GM B
- I
CSF I
expression O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
can O
occur O
independently O
of O
interleukin B
2 I
regulation O
and O
is O
probably O
mediated O
through O
cellular B
1 I
, I
25 I
( I
OH I
) I
2D3 I
receptors I
. O

Treatment O
of O
NK O
effectors O
with O
a O
monoclonal B
anti I
- I
human I
corticosteroid I
- I
binding I
globulin I
( I
CBG I
) I
antibody I
produced O
an O
enhancement O
of O
the O
spontaneous O
NK O
activity O
and O
a O
partial O
suppression O
of O
cortisol O
- O
mediated O
effects O
. O

All O
human B
and I
murine I
immunoglobulin I
heavy I
chain I
variable I
region I
( I
VH I
) I
genes I
contain O
the O
sequence O
ATGCAAAT O
approximately O
70 O
nucleotides O
5 O
' O
from O
the O
site O
of O
transcription O
initiation O
. O

This O
octanucleotide O
, O
in O
reverse O
orientation O
, O
is O
also O
found O
in O
all O
light B
chain I
variable I
region I
( I
VL I
) I
genes I
, O
and O
in O
the O
immunoglobulin B
heavy I
chain I
transcriptional I
enhancer I
. O

The O
second O
element B
is O
found O
upstream O
of O
both O
heavy B
and I
kappa I
light I
- I
chain I
gene I
promoters I
. O

We O
report O
here O
the O
identification O
of O
a O
human B
B I
- I
cell I
nuclear I
factor I
( O
IgNF B
- I
A I
) O
that O
binds O
to O
DNA B
sequences I
in O
the O
upstream B
regions I
of O
both O
the O
mouse B
heavy I
and I
kappa I
light I
- I
chain I
gene I
promoters I
and O
also O
to O
the O
mouse B
heavy I
- I
chain I
gene I
enhancer I
. O

Fibrinogen B
also O
caused O
activation O
of O
AP B
- I
1 I
, O
but O
not O
SP1 B
or O
cAMP B
response I
element I
- I
binding I
protein I
( I
CREB I
) I
factors I
. O

We O
report O
that O
activation O
of O
the O
two O
transcription B
factors I
NF I
- I
kappa I
B I
and I
AP I
- I
1 I
is O
crucially O
involved O
in O
FasL B
expression O
induced O
by O
etoposide O
, O
teniposide O
, O
and O
UV O
irradiation O
. O

Mutations O
in O
the O
relevant O
NF B
- I
kappa I
B I
and I
AP I
- I
1 I
binding I
sites I
eliminated O
these O
responses O
. O

Mycobacterium O
tuberculosis O
mannose O
- O
capped O
lipoarabinomannan O
can O
induce O
NF B
- I
kappaB I
- O
dependent O
activation O
of O
human B
immunodeficiency I
virus I
type I
1 I
long I
terminal I
repeat I
in O
T O
cells O
. O

M O
. O
tuberculosis O
ManLAM O
resulted O
in O
clear O
induction O
of O
the O
luciferase B
gene I
placed O
under O
the O
control O
of O
the O
wild B
- I
type I
, I
but I
not I
the I
kappaB I
- I
mutated I
, I
HIV I
- I
1 I
LTR I
region I
. O

Human B
immunodeficiency I
virus I
type I
1 I
long I
terminal I
repeat I
quasispecies O
differ O
in O
basal O
transcription O
and O
nuclear O
factor O
recruitment O
in O
human O
glial O
cells O
and O
lymphocytes O
. O

In O
particular O
, O
naturally O
occurring O
sequence O
variation O
impacted O
transcription B
factor I
binding O
to O
an O
activating B
transcription I
factor I
/ O
cAMP B
response I
element I
binding I
( O
ATF B
/ O
CREB B
) O
binding O
site O
( O
located O
between O
the O
LEF B
- I
1 I
and I
distal I
NF I
- I
kappaB I
transcription I
factor I
binding I
sites I
) O
that O
we O
identified O
in O
previous O
studies O
of O
the O
HIV B
- I
1 I
LTR I
. O

Among O
several O
known O
transcription B
factor I
binding I
motifs I
, O
nuclear B
protein I
( I
s I
) I
of O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
bound O
to O
the O
CCAAT B
/ I
enhancer I
binding I
protein I
( I
C I
/ I
EBP I
) I
- I
binding I
motif I
that O
was O
located O
in O
the O
upstream B
region I
of O
the O
MRP14 B
gene I
( O
- O
81 O
) O
, O
as O
evidenced O
by O
the O
competitive O
gel O
mobility O
- O
shift O
assay O
. O

Recombination O
of O
the O
MPC11 B
plasma I
B I
- I
cell I
derived I
NF I
- I
Y I
A I
: I
B I
: I
C I
complex I
with O
the O
low O
molecular O
mass O
protein O
fraction O
, O
NF B
- I
Y I
- I
associated I
factors I
( O
YAFs B
) O
, O
derived O
from O
mature O
A20 O
B O
- O
cell O
nuclei O
, O
conferred O
high O
affinity O
anion O
exchange O
binding O
to O
NF B
- I
Y I
as O
an O
intact B
trimeric I
complex I
. O

Recombination O
of O
the O
native B
NF I
- I
YA I
: I
B I
: I
C I
complex I
with O
the O
transcriptional B
cofactor I
, O
PC4 B
, O
likewise O
conferred O
high B
affinity I
NF I
- I
Y I
binding O
to O
anion B
exchangers I
, O
and O
stabilized O
NF B
- I
Y I
interaction O
with O
CCAAT B
- I
box I
DNA I
motifs I
in O
vitro O
. O

Interaction O
between O
PC4 B
and O
NF B
- I
Y I
was O
mapped O
to O
the O
C B
- I
terminal I
region I
of O
PC4 B
, O
and O
the O
subunit B
interaction I
subdomain I
of O
the O
highly B
conserved I
DNA I
binding I
- I
subunit I
interaction I
domain I
( O
DBD B
) O
of O
NF B
- I
YA I
. O

Induction O
of O
early B
B I
cell I
factor I
( O
EBF B
) O
and O
multiple B
B I
lineage I
genes I
by O
the O
basic B
helix I
- I
loop I
- I
helix I
transcription I
factor I
E12 B
. O

Specific O
forms O
of O
HIV O
- O
associated O
NHL O
are O
linked O
to O
expression O
of O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
- I
latent I
proteins I
; O
the O
newly O
described O
DNA O
virus O
, O
Karposi O
' O
s O
sarcoma O
- O
associated O
herpesvirus O
/ O
human O
herpesvirus O
- O
8 O
( O
KSHV O
/ O
HHV O
- O
8 O
) O
; O
and O
perhaps O
HIV O
. O

Inactivation O
of O
the O
NF B
- I
kappaB I
and I
3 I
' I
NF I
- I
IL I
- I
6 I
DNA I
binding I
sites I
decreased O
IL B
- I
8 I
gene I
transcriptional O
activation O
in O
response O
to O
TNF B
while O
inactivation O
of O
the O
5 B
' I
NF I
- I
IL I
- I
6 I
binding I
site I
increased O
IL B
- I
8 I
gene I
transcriptional O
activity O
in O
response O
to O
TNF B
. O

Inactivation O
of O
the O
NF B
- I
kappaB I
and I
3 I
' I
NF I
- I
IL I
- I
6 I
DNA I
binding I
sites I
decreased O
IL B
- I
8 I
gene I
transcriptional O
activation O
in O
response O
to O
TNF B
while O
inactivation O
of O
the O
5 B
' I
NF I
- I
IL I
- I
6 I
binding I
site I
increased O
IL B
- I
8 I
gene I
transcriptional O
activity O
in O
response O
to O
TNF B
. O

We O
now O
show O
that O
transcription B
factor I
early I
- I
growth I
- I
response I
gene I
product I
( O
Egr B
- I
1 I
) O
is O
rapidly O
activated O
in O
hypoxia O
, O
both O
in O
vitro O
and O
in O
vivo O
, O
and O
is O
responsible O
for O
transcription O
and O
expression O
of O
tissue B
factor I
in O
hypoxic O
lung O
. O

Anti O
- O
CD3 O
- O
restimulated O
T O
cells O
( O
mainly O
CD8 O
+ O
) O
produced O
IL B
- I
2 I
, O
interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
and O
tumour B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
and O
low O
levels O
of O
IL B
- I
4 I
and I
IL I
- I
10 I
transcripts I
and O
proteins O
. O

Anti O
- O
CD3 O
- O
stimulated O
IL B
- I
2 I
gene I
expression O
was O
down O
- O
regulated O
by O
protein O
synthesis O
inhibitor O
, O
whereas O
IL B
- I
10 I
, I
IFN I
- I
gamma I
and I
TNF I
- I
alpha I
genes I
were O
readily O
induced O
independent O
of O
ongoing O
protein O
synthesis O
. O

T B
- I
cell I
receptor I
stimulation O
also O
induced O
a O
very O
rapid O
expression O
of O
c B
- I
jun I
, I
c I
- I
fos I
and I
NFATc1 I
( I
NFATc I
) I
genes I
, O
the O
gene O
products O
of O
which O
are O
involved O
in O
cytokine O
gene O
expression O
. O

We O
report O
that O
exposure O
of O
primary O
rat O
microglia O
and O
human O
THP1 O
monocytes O
to O
fibrillar B
Abeta I
results O
in O
the O
tyrosine B
kinase I
- O
dependent O
activation O
of O
two O
parallel O
signal O
transduction O
cascades O
involving O
members O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPK I
) I
superfamily I
. O

Transcription B
factor I
B I
- I
cell I
- I
specific I
activator I
protein I
( O
BSAP B
) O
is O
differentially O
expressed O
in O
B O
cells O
and O
in O
subsets O
of O
B O
- O
cell O
lymphomas O
. O

Isolation O
and O
analysis O
of O
a O
T O
cell O
clone O
variant O
exhibiting O
constitutively O
phosphorylated B
Ser133 I
cAMP I
response I
element I
- I
binding I
protein I
. O

Significant O
mutations O
were O
not O
observed O
in O
c B
- I
MYC I
, I
S14 I
, I
or I
alpha I
- I
fetoprotein I
( I
AFP I
) I
genes I
, O
but O
BCL B
- I
6 I
was O
highly O
mutated O
in O
a O
large O
proportion O
of O
memory O
B O
cells O
of O
normal O
individuals O
. O

A O
family O
of O
hematopoietic B
specific I
transcription I
factors I
, O
MIP B
- I
1 I
alpha I
nuclear I
protein I
( I
MNP I
) I
family I
, O
has O
recently O
been O
identified O
. O

Overexpression O
of O
Bcl B
- I
3 I
in O
TF O
- O
1 O
cells O
by O
transient O
transfection O
along O
with O
the O
NF B
- I
kappaB I
factors I
p50 I
or I
p52 I
resulted O
in O
significant O
induction O
of O
an O
human B
immunodeficiency I
virus I
- I
type I
1 I
( I
HIV I
- I
1 I
) I
kappaB I
- I
TATA I
- I
luceriferase I
reporter I
plasmid I
, O
demonstrating O
that O
Bcl B
- I
3 I
has O
a O
positive O
role O
in O
transactivation O
of O
kappaB B
- I
containing I
genes I
in O
erythroid O
cells O
. O

Furthermore O
, O
cotransfection O
of O
Bcl B
- I
3 I
with O
p52 B
or O
p50 B
in O
TF O
- O
1 O
cells O
resulted O
in O
significant O
activation O
of O
a O
c B
- I
myb I
kappaB I
- I
TATA I
- I
luceriferase I
reporter I
plasmid I
. O

A O
synthetic O
peptide O
consisting O
of O
the O
Kaposi B
fibroblast I
growth I
factor I
signal I
sequence I
fused O
to O
the O
5 B
- I
lipoxygenase639 I
- I
656 I
bipartite I
nuclear I
localizing I
sequence I
has O
a O
prominent O
inhibitory O
effect O
on O
5 B
- I
lipoxygenase I
catalysis O
in O
granulocytic O
HL O
- O
60 O
cells O
activated O
by O
calcium O
ionophor O
A23187 O
. O

5 B
- I
Lipoxygenase I
protein I
was O
detected O
in O
nuclear B
factor I
kappaB I
( I
NF I
- I
kappaB I
) I
p65 I
subunit I
immunoprecipitate O
fractions O
prepared O
from O
HL O
- O
60 O
cell O
lysates O
. O

The O
intracellular O
incorporation O
of O
Abs O
specific O
for O
c B
- I
Fos I
and I
c I
- I
Jun I
family I
members I
by O
scrape O
loading O
inhibited O
the O
production O
and O
intracellular O
accumulation O
of O
IL B
- I
2 I
within O
6 O
h O
of O
costimulation O
with O
PMA O
/ O
ionomycin O
, O
or O
costimulation O
by O
CD28 O
and O
CD3 O
ligation O
. O

Furthermore O
, O
expression O
of O
a O
luciferase B
reporter I
gene I
driven O
by O
the O
NGFI B
- I
B I
( I
rat I
homolog I
of I
TR3 I
/ I
Nur77 I
) I
response I
element I
( O
NBRE B
) O
provided O
evidence O
that O
Tax B
- O
mediated O
transactivation O
resulted O
in O
the O
induction O
of O
a O
functional O
protein O
. O

A O
signaling O
complex O
of O
Ca2 B
+ I
- I
calmodulin I
- I
dependent I
protein I
kinase I
IV I
and O
protein B
phosphatase I
2A I
[ O
see O
comments O
] O

Stimulation O
of O
T O
lymphocytes O
results O
in O
a O
rapid O
increase O
in O
intracellular O
calcium O
concentration O
( O
[ O
Ca2 O
+ O
] O
i O
) O
that O
parallels O
the O
activation O
of O
Ca2 B
+ I
- I
calmodulin I
- I
dependent I
protein I
kinase I
IV I
( O
CaMKIV B
) O
, O
a O
nuclear B
enzyme I
that O
can O
phosphorylate O
and O
activate O
the O
cyclic B
adenosine I
monophosphate I
( I
cAMP I
) I
response I
element I
- I
binding I
protein I
( O
CREB B
) O
. O

Stimulation O
of O
T O
lymphocytes O
results O
in O
a O
rapid O
increase O
in O
intracellular O
calcium O
concentration O
( O
[ O
Ca2 O
+ O
] O
i O
) O
that O
parallels O
the O
activation O
of O
Ca2 B
+ I
- I
calmodulin I
- I
dependent I
protein I
kinase I
IV I
( O
CaMKIV B
) O
, O
a O
nuclear B
enzyme I
that O
can O
phosphorylate O
and O
activate O
the O
cyclic B
adenosine I
monophosphate I
( I
cAMP I
) I
response I
element I
- I
binding I
protein I
( O
CREB B
) O
. O

Hypoxia O
down O
- O
regulated O
TNF B
- I
alpha I
- I
induced I
MCP I
- I
1 I
mRNA I
and O
protein O
production O
by O
ovarian O
cancer O
cells O
. O

OBJECTIVE O
: O
The O
redox B
- I
sensitive I
transcription I
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
is O
believed O
to O
contribute O
to O
late O
diabetic O
complications O
. O

Notably O
, O
among O
AIDS O
- O
related O
PCNSL O
, O
expression O
of O
BCL B
- I
6 I
was O
mutually O
exclusive O
with O
expression O
of O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
- I
encoded I
latent I
membrane I
protein I
( I
LMP I
) I
- I
1 I
and O
, O
with O
few O
exceptions O
, O
also O
of O
BCL B
- I
2 I
. O

The O
mammalian B
E2A I
, I
HEB I
, I
and I
E2 I
- I
2 I
genes I
encode O
a O
unique O
class O
of O
basic B
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
transcription I
factors I
that O
are O
evolutionarily O
conserved O
and O
essential O
for O
embryonic O
and O
postnatal O
development O
. O

The O
mammalian B
E2A I
, I
HEB I
, I
and I
E2 I
- I
2 I
genes I
encode O
a O
unique O
class O
of O
basic B
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
transcription I
factors I
that O
are O
evolutionarily O
conserved O
and O
essential O
for O
embryonic O
and O
postnatal O
development O
. O

The O
human B
DR3 I
gene I
, O
whose O
product O
is O
also O
known O
as O
Wsl B
- I
1 I
/ I
APO I
- I
3 I
/ I
TRAMP I
/ I
LARD I
, O
encodes O
a O
tumor B
necrosis I
factor I
- I
related I
receptor I
that O
is O
expressed O
primarily O
on O
the O
surface O
of O
thymocytes O
and O
lymphocytes O
. O

We O
report O
here O
that O
the O
DR3 B
gene I
locus I
is O
tandemly O
duplicated O
on O
human B
chromosome I
band I
1p36 I
. I
2 I
- I
p36 I
. I
3 I
and O
that O
these O
genes O
are O
hemizygously O
deleted O
and O
/ O
or O
translocated O
to O
another O
chromosome O
in O
neuroblastoma O
( O
NB O
) O
cell O
lines O
with O
amplified O
MYCN O
. O

We O
have O
investigated O
this O
syndrome O
for O
the O
possibility O
of O
abnormal B
Type I
I I
or O
` B
` I
mineralocorticoid I
- I
like I
' I
' I
receptors I
, O
which O
have O
intrinsic O
steroid O
specificity O
indistinguishable O
from O
that O
of O
renal B
mineralocorticoid I
receptors I
and O
are O
found O
in O
many O
tissues O
and O
cells O
, O
including O
mononuclear O
leukocytes O
. O

Both O
cell O
types O
secrete O
a O
urokinase B
( I
UK I
) I
- I
like I
plasminogen I
activator I
( O
PA B
) O
. O

No O
significant O
changes O
were O
observed O
in O
the O
serum O
peptide O
hormone O
concentrations O
measured O
( O
FSH O
, O
LH O
, O
prolactin O
, O
insulin O
, O
growth O
hormone O
and O
TSH O
) O
; O
neither O
were O
the O
levels O
of O
endometrial B
ERC I
, I
ERN I
, I
PRC I
and I
PRN I
affected O
by O
interferon B
administration O
. O

Resting O
T O
- O
cells O
do O
not O
express O
IL B
- I
2 I
receptors I
, O
but O
receptors O
are O
rapidly O
expressed O
on O
T O
- O
cells O
following O
interaction O
of O
antigens O
, O
mitogens O
, O
or O
monoclonal B
antibodies I
with O
the O
antigen B
- I
specific I
T I
- I
cell I
receptor I
complex I
. O

Antisera O
were O
obtained O
following O
immunization O
of O
New O
Zealand O
White O
rabbits O
with O
[ B
3H I
] I
triamcinolone I
acetonide I
[ I
( I
3H I
] I
TA I
) I
- I
glucocorticoid I
receptor I
complexes I
partially O
purified O
by O
two O
- O
stage O
DNA O
- O
cellulose O
chromatography O
. O

The O
presence O
of O
anti B
- I
human I
glucocorticoid I
receptor I
antibodies I
was O
verified O
by O
: O
( O
a O
) O
adsorption O
of O
[ B
3H I
] I
TA I
- I
receptor I
- I
antibody I
complexes I
to O
Protein B
A I
; O
( O
b O
) O
a O
shift O
to O
higher O
apparent O
molecular O
weight O
in O
the O
elution O
position O
from O
Sephacryl O
S300 O
of O
[ B
3H I
] I
TA I
- I
receptor I
complexes I
incubated O
with O
immune O
serum O
; O
and O
( O
c O
) O
the O
ability O
of O
immune O
serum O
to O
displace O
[ B
3H I
] I
TA I
- I
receptor I
complexes I
on O
sucrose O
gradients O
. O

Resting O
human O
peripheral O
blood O
T O
lymphocytes O
, O
however O
, O
do O
not O
have O
a O
demonstrable O
1 B
, I
25 I
- I
( I
OH I
) I
2D3 I
receptor I
. O

These O
results O
are O
consistent O
with O
the O
finding O
that O
specific O
1 B
, I
25 I
- I
( I
OH I
) I
2D3 I
receptors I
are O
present O
on O
the O
T O
cell O
hybridomas O
but O
are O
lacking O
in O
TA3 O
cells O
. O

Two O
hundred O
and O
eighty O
- O
eight O
primary O
breast O
tumours O
were O
examined O
for O
the O
presence O
or O
absence O
of O
oestrogen B
( I
REc I
) I
and I
progesterone I
( I
RPc I
) I
receptors I
. O

Overexpression O
of O
Rel B
proteins I
demonstrated O
that O
p65 O
- O
expressing O
Jurkat O
cells O
transcribed O
equally O
well O
a O
nuclear B
factor I
kappabeta I
reporter I
construct I
when O
costimulated O
with O
B7 B
- I
1 I
or O
LFA B
- I
3 I
, O
but O
transcription O
of O
IL B
- I
2 I
promoter I
or O
CD28 B
response I
element I
( I
CD28RE I
) I
- I
driven I
reporters I
was O
superior O
in O
B7 O
- O
1 O
- O
costimulated O
cells O
. O

Combined O
expression O
of O
c B
- I
Jun I
and O
p65 B
induced O
vigorous O
transcription O
of O
IL B
- I
2 I
promoter I
- I
and I
CD28RE I
- I
driven I
reporter I
constructs I
in O
both O
LFA O
- O
3 O
- O
and O
B7 O
- O
1 O
- O
costimulated O
Jurkat O
cells O
. O

Activation O
of O
Jun B
N I
- I
terminal I
kinase I
or O
stress B
- I
activated I
kinase I
( O
JNK B
or O
SAPK B
) O
and O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
the O
induction O
of O
the O
transcription B
factor I
NF B
- I
ATc1 I
and I
egr I
- I
1 I
genes I
was O
normal O
. O

Therefore O
, O
P B
- I
CREB I
was O
evaluated O
following O
co O
- O
stimulation O
of O
human O
PBMC O
through O
the O
IL B
- I
2 I
and I
CD2 I
or I
CD3 I
receptors I
. O

HTLV B
- I
1 I
p12 I
( I
I I
) I
protein I
enhances O
STAT5 O
activation O
and O
decreases O
the O
interleukin B
- I
2 I
requirement O
for O
proliferation O
of O
primary O
human O
peripheral O
blood O
mononuclear O
cells O
. O

This O
study O
demonstrated O
that O
p12 B
( I
I I
) I
binds O
to O
the O
cytoplasmic B
domain I
of O
the O
interleukin B
- I
2 I
receptor I
( I
IL I
- I
2R I
) I
beta I
chain I
that O
is O
involved O
in O
the O
recruitment O
of O
the O
Jak1 B
and I
Jak3 I
kinases I
. O

As O
a O
result O
of O
this O
interaction O
, O
p12 B
( I
I I
) I
increases O
signal B
transducers I
and I
activators I
of I
transcription I
5 I
( O
STAT5 B
) O
DNA O
binding O
and O
transcriptional O
activity O
and O
this O
effect O
depends O
on O
the O
presence O
of O
both O
IL B
- I
2R I
beta I
and I
gamma I
( I
c I
) I
chains I
and O
Jak3 B
. O

Transduction O
of O
primary O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
with O
a O
human B
immunodeficiency I
virus I
type I
1 I
- I
based I
retroviral I
vector I
expressing O
p12 B
( I
I I
) I
also O
resulted O
in O
increased O
STAT5 B
phosphorylation O
and O
DNA O
binding O
. O

Regulation O
of O
interleukin B
( I
IL I
) I
- I
18 I
receptor I
alpha I
chain I
expression O
on O
CD4 O
( O
+ O
) O
T O
cells O
during O
T O
helper O
( O
Th O
) O
1 O
/ O
Th2 O
differentiation O
. O

Interleukin B
( I
IL I
) I
- I
18 I
has O
been O
well O
characterized O
as O
a O
costimulatory B
factor I
for O
the O
induction O
of O
IL B
- I
12 I
- I
mediated I
interferon I
( I
IFN I
) I
- I
gamma I
production O
by O
T O
helper O
( O
Th O
) O
1 O
cells O
, O
but O
also O
can O
induce O
IL O
- O
4 O
production O
and O
thus O
facilitate O
the O
differentiation O
of O
Th2 O
cells O
. O

Inhibition O
of O
pro B
- I
inflammatory I
transcription I
factors I
such O
as O
activator B
protein I
( I
AP I
) I
- I
1 I
, O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STATs B
) O
, O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
and O
nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
is O
thought O
to O
be O
a O
major O
action O
of O
glucocorticoids O
. O

In O
the O
process O
of O
neoplastic O
transformation O
, O
the O
EBV B
- I
encoded I
latent I
membrane I
protein I
1 I
( I
LMP1 I
) I
oncogene I
represents O
the O
major O
driving O
force O
. O

LMP1 B
acts O
like O
a O
constitutively B
activated I
receptor I
of O
the O
tumor B
necrosis I
factor I
receptor I
family I
and O
allows O
the O
amplification O
or O
bypassing O
of O
physiological O
regulatory O
signals O
through O
direct O
and O
indirect O
interactions O
with O
proteins O
of O
the O
tumor B
necrosis I
factor I
receptor I
- I
associated I
factor I
( I
TRAF I
) I
family I
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
BMP B
- I
2 I
activated O
the O
mouse O
p21 B
( I
CIP1 I
/ I
WAF1 I
) I
promoter I
in O
HS O
- O
72 O
cells O
, O
and O
that O
a O
29 B
- I
base I
pair I
( I
b I
) I
region I
of O
the O
promoter O
( O
- O
1928 O
/ O
- O
1900 O
relative O
to O
the O
TATA B
box I
) O
, O
conserved O
between O
mice O
and O
humans O
, O
was O
responsive O
to O
BMP B
- I
2 I
as O
well O
as O
expression O
of O
Smad1 B
, O
Smad4 B
, O
and O
constitutively O
active O
mutants O
of O
BMP B
type I
I I
receptors I
. O

Macrophage O
stimulation O
with O
Murabutide O
, O
an O
HIV O
- O
suppressive O
muramyl O
peptide O
derivative O
, O
selectively O
activates O
extracellular B
signal I
- I
regulated I
kinases I
1 I
and I
2 I
, O
C B
/ I
EBPbeta I
and O
STAT1 B
: O
role O
of O
CD14 B
and O
Toll B
- I
like I
receptors I
2 I
and I
4 I
. O

We O
demonstrate O
that O
, O
unlike O
LPS O
, O
the O
safe O
immunomodulator O
MB O
selectively O
activates O
extracellular B
signal I
- I
regulated I
kinases I
( I
Erk I
) I
1 I
/ I
2 I
, O
in O
the O
absence O
of O
detectable O
Jun B
N I
- I
terminal I
kinase I
( O
JNK B
) O
or O
p38 B
mitogen I
- I
activated I
kinase I
activation O
. O

Nuclear B
peroxisome I
proliferator I
- I
activated I
receptors I
alpha I
and I
gamma I
have O
opposing O
effects O
on O
monocyte O
chemotaxis O
in O
endometriosis O
. O

The O
peroxisome B
proliferator I
- I
activated I
receptors I
( I
PPARs I
) I
alpha I
and I
gamma I
are O
nuclear B
receptors I
that O
play O
important O
roles O
in O
inflammatory O
diseases O
like O
ulcerative O
colitis O
and O
arthritis O
. O

Nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
expression O
and O
dimer O
characteristics O
were O
studied O
in O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
of O
major O
- O
trauma O
patients O
and O
healthy O
controls O
. O

Murine B
FOG I
- I
1 I
and I
FOG I
- I
2 I
also O
can O
repress O
crystal O
cell O
production O
, O
but O
a O
mutant O
version O
of O
FOG B
- I
2 I
lacking O
a O
conserved O
motif O
that O
binds O
the O
corepressor B
C I
- I
terminal I
binding I
protein I
fails O
to O
affect O
the O
cell O
lineage O
. O

Thus O
, O
TCF B
- I
1 I
, O
upon O
association O
with O
beta O
- O
catenin O
, O
transiently O
ensures O
the O
survival O
of O
immature O
T O
cells O
, O
which O
enables O
them O
to O
generate O
and O
edit O
T B
cell I
receptor I
( I
TCR I
) I
alpha I
chains I
and O
attempt O
TCR B
- O
mediated O
positive O
selection O
. O

Preclinical O
in O
vitro O
and O
in O
vivo O
evaluations O
were O
performed O
to O
assess O
the O
potential O
therapeutic O
applications O
of O
human O
recombinant O
tumor B
necrosis I
factor I
( I
TNF I
) I
- I
related I
apoptosis I
- I
inducing I
ligand I
/ I
Apo2 I
ligand I
( O
TRAIL B
/ I
Apo2L I
) O
in O
MM O
. O

Recent O
data O
from O
mice O
deficient O
for O
phosphatase B
and O
tensin B
homologue I
deleted O
from O
chromosome B
10 I
or O
src B
homology I
2 I
domain I
- I
containing I
5 I
' I
inositol I
phosphatase I
, O
phosphatases B
that O
negatively O
regulate O
the O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI3K B
) O
pathway O
, O
revealed O
an O
increased O
number O
of O
macrophages O
in O
these O
animals O
, O
suggesting O
an O
essential O
role O
for O
the O
PI3K B
pathway O
for O
macro O
- O
phage O
survival O
. O

Furthermore O
, O
suppression O
of O
Akt B
- I
1 I
by O
inhibition O
of O
PI3K B
or O
a O
dominant B
negative I
( I
DN I
) I
Akt I
- I
1 I
resulted O
in O
loss O
of O
mitochondrial O
transmembrane O
potential O
, O
activation O
of O
caspases B
- I
9 I
and I
- I
3 I
, O
and O
DNA O
fragmentation O
. O

Analysis O
of O
the O
minimal B
promoter I
revealed O
nine O
consensus B
- I
binding I
sites I
for O
transcription B
factors I
, O
including O
several O
that O
are O
also O
found O
in O
the O
minimal B
promoters I
of O
galectins B
- I
1 I
, I
- I
2 I
, I
and I
- I
3 I
. O

Calcineurin B
, O
a O
Ca B
( I
2 I
+ I
) I
/ I
calmodulin I
- I
dependent I
Ser I
/ I
Thr I
phosphatase I
( I
protein I
phosphatase I
2B I
) I
, O
plays O
a O
critical O
role O
in O
IL O
- O
2 O
production O
during O
T O
cell O
activation O
. O

The O
cells O
were O
matured O
by O
addition O
of O
tumor B
necrosis I
factor I
( I
TNF I
) I
- I
a I
, O
IL B
- I
1 I
beta I
, O
and O
prostaglandin B
E2 I
in O
the O
presence O
of O
sulfasalazine O
or O
its O
metabolites O
- O
- O
aminosalicylate O
and O
sulfapyridine O
, O
or O
their O
combinations O
. O

We O
quantified O
the O
effect O
of O
drugs O
on O
the O
dendritic O
cell O
characteristics O
, O
such O
as O
stimulation O
of O
autologous O
and O
allogeneic O
pan O
- O
T O
cell O
proliferation O
, O
surface O
marker O
phenotype O
, O
IL O
- O
12 O
p40 O
subunit O
secretion O
, O
and O
activation O
of O
nuclear B
transcription I
factor I
( I
NF I
) I
- I
kappa I
B I
. O

OX40 B
is O
a O
member O
of O
the O
tumor B
necrosis I
factor I
( I
TNF I
) I
receptor I
superfamily I
and O
known O
to O
be O
an O
important O
costimulatory B
molecule I
expressed O
on O
activated O
T O
cells O
. O

Directed O
alterations O
in O
the O
accessibility O
of O
V B
, I
D I
, I
and I
J I
gene I
segments I
target O
the O
recombinase B
to O
specific O
Ag B
receptor I
loci I
. O

BTK B
phosphorylated O
the O
Y665F B
, I
Y668F I
, I
and I
Y682F I
, I
Y683F I
mutants I
but O
not O
the O
Y694F B
mutant I
of O
STAT5A B
. O

STAT5A O
mutations O
in O
the O
Src B
homology I
2 I
( I
SH2 I
) I
and I
SH3 I
domains I
did O
not O
alter O
the O
BTK B
- O
mediated O
tyrosine O
phosphorylation O
. O

We O
show O
that O
T B
- I
bet I
, O
without O
apparent O
assistance O
from O
interleukin B
12 I
( I
IL I
- I
12 I
) I
/ O
STAT4 B
, O
specifies O
TH1 O
effector O
fate O
by O
targeting O
chromatin O
remodeling O
to O
individual O
interferon B
- I
gamma I
( I
IFN I
- I
gamma I
) I
alleles I
and O
by O
inducing O
IL B
- I
12 I
receptor I
beta2 I
expression O
. O

To O
determine O
the O
roles O
of O
the O
phosphotyrosine B
binding I
adaptors I
in O
Th2 O
differentiation O
, O
we O
prepared O
a O
retrovirus O
containing O
a O
mutant O
of O
the O
human B
( I
h I
) I
IL I
- I
4R I
alpha I
- I
chain I
, O
Y497F B
, O
which O
is O
unable O
to O
recruit O
these O
adaptors O
. O

The O
mutant B
hIL I
- I
4Ralpha I
, O
as O
well O
as O
the O
wild B
- I
type I
( I
WT I
) I
hIL I
- I
4Ralpha I
, O
was O
introduced O
into O
naive O
CD4 O
T O
cells O
. O

In O
nonstimulated O
T O
cells O
a O
repressor O
complex O
containing O
NF B
- I
IL6 I
, O
JunB B
, O
c B
- I
Fos I
and O
Fra B
- I
1 I
is O
formed O
on O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
and O
represses O
IL B
- I
2 I
promoter I
activity O
. O

After O
T O
cell O
activation O
, O
a O
heterodimeric B
activator I
containing O
p65 B
and O
c B
- I
Jun I
binds O
to O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
. O

HIV B
Tat I
enhances O
activation O
of O
NF B
- I
kappaB I
and O
consequently O
, O
activates O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
. O

OBJECTIVE O
: O
Thrombopoietin B
( O
TPO B
) O
and O
transforming B
growth I
factor I
- I
beta I
( I
1 I
) I
( O
TGF B
- I
beta I
( I
1 I
) I
) O
have O
been O
shown O
to O
exert O
opposite O
effects O
on O
proliferation O
and O
megakaryocytic O
differentiation O
of O
hematopoietic O
cells O
. O

Invariant B
chain I
induces O
B O
cell O
maturation O
by O
activating O
a O
TAF B
( I
II I
) I
105 I
- I
NF I
- I
kappaB I
- O
dependent O
transcription O
program O
. O

Our O
studies O
indicate O
that O
Ii B
- O
induced O
B O
cell O
maturation O
involves O
activation O
of O
transcription O
mediated O
by O
the O
NF B
- I
kappaB I
p65 I
/ I
RelA I
homodimer I
and O
requires O
the O
B B
cell I
- I
enriched I
coactivator I
TBP B
- I
associated I
factor I
( I
II I
) I
105 I
. O

High O
constitutive O
expression O
of O
the O
IFNgamma B
- I
inducible I
genes I
, O
IFN B
- I
stimulated I
gene I
factor I
3 I
gamma I
subunit I
( O
ISGF3gamma B
) O
, O
IFN B
regulatory I
factor I
- I
1 I
( O
IRF B
- I
1 I
) O
, O
and O
the O
cyclin B
- I
dependent I
kinase I
inhibitor I
p21 I
( O
WAF1 B
) O
was O
found O
in O
FANCC B
mutant O
B O
lymphoblasts O
, O
low O
- O
density O
bone O
marrow O
cells O
, O
and O
murine O
embryonic O
fibroblasts O
. O

Paradoxically O
, O
these O
cells O
do O
not O
activate B
signal I
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
1 I
properly O
. O

The O
basic B
- I
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
transcription I
factors I
encoded O
by O
the O
E2A B
gene I
are O
involved O
in O
several O
differentiation O
events O
during O
B O
and O
T O
cell O
development O
, O
including O
lineage O
commitment O
, O
initiation O
of O
V O
( O
D O
) O
J O
recombination O
, O
and O
antigen O
receptor O
mediated O
proliferation O
and O
differentiation O
. O

GILZ B
also O
potently O
inhibited O
AP B
- I
1 I
- I
driven I
and I
IL I
- I
2 I
promoter I
- I
driven I
reporter I
constructs I
, O
and O
recombinant O
GILZ B
specifically O
interacted O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
in O
vitro O
and O
inhibited O
the O
binding O
of O
active B
AP I
- I
1 I
to O
its O
target O
DNA O
. O

Transforming B
growth I
factor I
( I
TGF I
) I
- I
beta1 I
is O
well O
established O
as O
a O
critical O
IgA B
isotype I
switching I
factor I
and O
Smad B
molecules I
have O
been O
reported O
to O
act O
as O
transducers B
and O
transcriptional B
factors I
in O
the O
expression O
of O
TGF B
- I
beta1 I
- O
targeted O
genes B
. O

First O
, O
we O
found O
that O
TGF B
- I
beta1 I
significantly O
increases O
endogenous B
germ I
- I
line I
( I
GL I
) I
alpha I
transcripts I
by O
LPS O
- O
stimulated O
CH12 O
. O
LX O
. O
4933 O
( O
mu O
( O
+ O
) O
) O
B O
lymphoma O
cells O
. O

Mutation O
of O
the O
distal B
( I
- I
105 I
/ I
- I
97 I
) I
and O
proximal B
( I
- I
76 I
/ I
- I
61 I
) I
NFAT B
response I
elements I
in O
the O
COX B
- I
2 I
promoter I
abolished O
the O
activation O
induced O
by O
Cot B
kinase I
. O

Mutation O
of O
the O
distal B
( I
- I
105 I
/ I
- I
97 I
) I
and O
proximal B
( I
- I
76 I
/ I
- I
61 I
) I
NFAT B
response I
elements I
in O
the O
COX B
- I
2 I
promoter I
abolished O
the O
activation O
induced O
by O
Cot B
kinase I
. O

Positive O
and O
negative O
roles O
of O
the O
trans B
- I
acting I
T I
cell I
factor I
- I
1 I
for O
the O
acquisition O
of O
distinct O
Ly B
- I
49 I
MHC I
class I
I I
receptors I
by O
NK O
cells O
. O

We O
show O
in O
this O
study O
, O
using O
TCF B
- I
1 I
beta I
( I
2 I
) I
- I
microglobulin I
double O
- O
deficient O
mice O
, O
that O
these O
repertoire O
alterations O
are O
not O
due O
to O
Ly O
- O
49 O
/ O
MHC O
class O
I O
interactions O
. O

Blockade O
of O
depletion O
of O
IkappaB B
- I
alpha I
by O
proteasome O
inhibitors O
( O
proteasome O
inhibitor O
I O
or O
acetyl O
- O
leucinyl O
- O
leucinyl O
- O
norleucinal O
) O
led O
to O
concomitant O
inhibition O
of O
NF O
- O
kappaB O
DNA O
- O
binding O
activity O
and O
expression O
of O
MIP B
- I
1alpha I
and I
MIP I
- I
1beta I
messenger I
RNA I
induced O
by O
beta O
( O
2 O
) O
integrin O
ligation O
. O

Synergistic O
transcriptional O
activation O
of O
human B
Acyl I
- I
coenzyme I
A I
: I
cholesterol I
acyltransterase I
- I
1 I
gene I
by O
interferon B
- I
gamma I
and O
all O
- O
trans O
- O
retinoic O
acid O
THP O
- O
1 O
cells O
. O

CML B
- I
modified I
albumin I
produced O
rapid O
transient O
activation O
of O
tyrosine O
phosphorylation O
, O
extracellular B
signal I
- I
regulated I
kinase I
1 I
and I
2 I
, O
and O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
, O
but O
not O
c B
- I
Jun I
NH I
( I
2 I
) I
- I
terminal I
kinase I
. O

CML B
- I
modified I
albumin I
produced O
rapid O
transient O
activation O
of O
tyrosine O
phosphorylation O
, O
extracellular B
signal I
- I
regulated I
kinase I
1 I
and I
2 I
, O
and O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
, O
but O
not O
c B
- I
Jun I
NH I
( I
2 I
) I
- I
terminal I
kinase I
. O

In O
Western O
blots O
using O
mAbs B
detecting O
phosphorylated B
STAT I
- I
3 I
, I
STAT I
- I
5 I
, I
STAT I
- I
6 I
, O
or O
extracellular B
signal I
- I
related I
kinase I
1 I
/ I
2 I
, O
we O
found O
that O
CD45R0 O
signaling O
could O
effectively O
diminish O
phosphorylation O
of O
these O
intracellular O
signaling O
components O
. O

In O
Western O
blots O
using O
mAbs B
detecting O
phosphorylated B
STAT I
- I
3 I
, I
STAT I
- I
5 I
, I
STAT I
- I
6 I
, O
or O
extracellular B
signal I
- I
related I
kinase I
1 I
/ I
2 I
, O
we O
found O
that O
CD45R0 O
signaling O
could O
effectively O
diminish O
phosphorylation O
of O
these O
intracellular O
signaling O
components O
. O

The O
four O
calcium O
- O
regulated O
transcription B
factors I
of O
the O
NFAT B
family I
act O
synergistically O
with O
AP B
- I
1 I
( I
Fos I
/ I
Jun I
) I
proteins I
on O
composite O
DNA O
elements O
which O
contain O
adjacent O
NFAT B
and I
AP I
- I
1 I
binding I
sites I
, O
where O
they O
form O
highly O
stable O
ternary O
complexes O
to O
regulate O
the O
expression O
of O
diverse O
inducible O
genes O
. O

Concomitant O
induction O
of O
NFAT B
and O
AP B
- I
1 I
requires O
concerted O
activation O
of O
two O
different O
signaling O
pathways O
: O
calcium O
/ O
calcineurin O
, O
which O
promotes O
NFAT O
dephosphorylation O
, O
nuclear O
translocation O
and O
activation O
; O
and O
protein B
kinase I
C I
( I
PKC I
) I
/ I
Ras I
, O
which O
promotes O
the O
synthesis O
, O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Fos B
and I
Jun I
families I
of O
transcription B
factors I
. O

Residues O
Tyr357 O
and O
Tyr462 O
are O
contained O
within O
the O
loop B
regions I
of O
adjacent O
helix B
- I
loop I
- I
helix I
- I
like I
repeats I
within O
BAP B
/ I
TFII I
- I
I I
. O

Mutation O
of O
either O
Tyr248 O
, O
Tyr357 O
, O
or O
Tyr462 O
to O
phenylalanine O
reduced O
transcription O
from O
a O
c B
- I
fos I
promoter I
relative O
to O
wild B
- I
type I
BAP I
/ I
TFII I
- I
I I
in O
transfected O
COS O
- O
7 O
cells O
, O
consistent O
with O
the O
interpretation O
that O
phosphorylation O
at O
these O
sites O
contributes O
to O
transcriptional O
activation O
. O

CD28 O
+ O
CD8 O
( O
+ O
) O
T O
cells O
unable O
to O
transcribe O
the O
IL B
- I
2 I
gene I
in O
response O
to O
antigenic O
stimulation O
had O
a O
block O
in O
transactivation O
of O
the O
- B
150 I
CD28 I
response I
element I
( I
CD28RE I
) I
/ I
AP I
- I
1 I
site I
of O
the O
IL B
- I
2 I
promoter I
, O
but O
did O
transactivate O
the O
composite O
NFAT B
/ I
AP I
- I
1 I
and I
OCT I
/ I
AP I
- I
1 I
sites I
, O
and O
a O
consensus B
AP I
- I
1 I
motif I
. O

CD28 O
+ O
CD8 O
( O
+ O
) O
T O
cells O
unable O
to O
transcribe O
the O
IL B
- I
2 I
gene I
in O
response O
to O
antigenic O
stimulation O
had O
a O
block O
in O
transactivation O
of O
the O
- B
150 I
CD28 I
response I
element I
( I
CD28RE I
) I
/ I
AP I
- I
1 I
site I
of O
the O
IL B
- I
2 I
promoter I
, O
but O
did O
transactivate O
the O
composite O
NFAT B
/ I
AP I
- I
1 I
and I
OCT I
/ I
AP I
- I
1 I
sites I
, O
and O
a O
consensus B
AP I
- I
1 I
motif I
. O

Mutation O
of O
the O
nonconsensus B
- I
150 I
AP I
- I
1 I
site I
to O
a O
consensus B
AP I
- I
1 I
site I
, O
or O
insertion O
of O
a O
CD28RE B
/ I
AP I
- I
1 I
consensus I
site I
upstream O
of O
the O
native O
- B
150 I
CD28RE I
/ I
AP I
- I
1 I
site I
restored O
transactivation O
of O
the O
altered O
promoter B
. O

In O
this O
report O
, O
we O
explore O
the O
mechanisms O
of O
targeting O
of O
p300 B
to O
the O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
in O
response O
to O
mitogenic O
and O
oncogenic O
molecular O
signals O
. O

Recruitment O
of O
p300 B
by O
cAMP B
- I
responsive I
element I
- I
binding I
protein I
- I
Rel I
cross O
- O
talk O
at O
the O
composite B
CD28 I
response I
element I
( O
CD28RE B
) O
- O
TRE B
element I
of O
the O
IL B
- I
2 I
promoter I
is O
essential O
for O
promoter O
inducibility O
during O
T O
- O
cell O
activation O
, O
and O
CD28RE B
- I
TRE I
is O
the O
exclusive O
target O
of O
the O
human O
T O
- O
cell O
lymphotropic O
virus O
type O
I O
oncoprotein B
Tax I
. O

The O
HSR O
reduced O
inflammatory O
gene O
expression O
in O
the O
brain O
that O
normally O
occurs O
during O
EAE O
, O
including O
the O
early O
increase O
in O
RANTES B
( O
regulated B
on I
activation I
of I
normal I
T I
- I
cell I
expressed I
and I
secreted I
) O
expression O
, O
and O
the O
later O
expression O
of O
the O
inducible O
form O
of O
nitric B
oxide I
synthase I
. O

In O
contrast O
, O
the O
CBFbeta B
- O
smooth B
muscle I
myosin I
heavy I
chain I
( I
SMMHC I
) I
fusion I
protein I
generated O
by O
the O
inv B
( I
16 I
) I
associated O
with O
acute O
myeloid O
leukemias O
( O
M4Eo O
) O
can O
not O
rescue O
definitive O
hematopoiesis O
by O
Cbfb O
- O
deficient O
ES O
cells O
. O

Our O
study O
demonstrated O
that O
all O
samples O
from O
the O
patients O
contained O
EBV B
nuclear I
antigen I
( I
EBNA I
) I
- I
1 I
mRNA I
which O
was O
transcribed O
using O
the O
Q B
promoter I
, O
whereas O
both O
the O
Q B
promoter I
and O
another O
upstream B
promoter I
( O
Cp B
/ I
Wp I
) O
were O
used O
in O
EBV O
- O
positive O
cell O
lines O
, O
B95 O
. O
8 O
, O
Raji O
and O
Jiyoye O
. O

Latent B
membrane I
protein I
- I
1 I
( I
LMP I
- I
1 I
) I
mRNA I
was O
detected O
in O
seven O
of O
eight O
patients O
and O
all O
cell O
lines O
, O
whereas O
EBNA B
- I
2 I
transcripts I
were O
found O
only O
in O
the O
cell O
lines O
. O

Immunostaining O
showed O
no O
LMP B
- I
1 I
, I
EBNA I
- I
2 I
or I
ZEBRA I
antigens I
in O
the O
paraffin O
- O
embedded O
tissue O
sections O
, O
although O
they O
were O
positive O
in O
the O
cell O
line O
cells O
. O

Our O
results O
indicate O
that O
the O
restricted O
expression O
of O
the O
latency B
- I
associated I
EBV I
genes I
and O
the O
production O
of O
vIL B
- I
10 I
and I
bcl I
- I
2 I
homologue I
may O
favour O
tumour O
growth O
, O
evading O
the O
host O
immune O
surveillance O
. O

Influenza O
A O
virus O
infection O
results O
in O
the O
production O
of O
chemotactic O
( O
RANTES B
, O
MIP B
- I
1 I
alpha I
, O
MCP B
- I
1 I
, O
MCP B
- I
3 I
, O
and O
IP B
- I
10 I
) O
, O
pro O
- O
inflammatory O
( O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
18 I
, O
and O
TNF B
- I
alpha I
) O
, O
and O
antiviral B
( I
IFN I
- I
alpha I
/ I
beta I
) I
cytokines I
. O

Peroxisome B
proliferator I
- I
activated I
receptor I
( I
PPAR I
) I
- I
gamma I
is O
a O
nuclear B
hormone I
receptor I
that O
serves O
as O
a O
trans O
factor O
to O
regulate O
lipid O
metabolism O
. O

SART3 O
derived O
peptides O
at O
positions B
109 I
- I
118 I
and I
315 I
- I
323 I
induced O
HLA O
- O
A24 O
restricted O
CTLs O
that O
reacted O
to O
breast O
cancer O
cells O
from O
the O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
of O
breast O
cancer O
patients O
. O

Gadd45gamma B
, O
a O
family O
member O
of O
the O
growth B
arrest I
and I
DNA I
damage I
- I
inducible I
gene I
family I
45 I
( O
Gadd45 B
) O
, O
is O
strongly O
induced O
by O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
in O
peripheral O
T O
cells O
. O

The O
basic B
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
proteins I
E12 B
and O
E47 B
and O
an O
inhibitor B
HLH I
protein I
, O
Id3 B
, O
play O
key O
roles O
in O
thymocyte O
differentiation O
. O

Investigation O
of O
retinoid B
receptor I
expression O
, O
known O
to O
mediate O
intracellular O
RA O
signaling O
, O
revealed O
presence O
of O
RAR B
alpha I
, I
RAR I
gamma I
, I
RXR I
beta I
, I
and I
RXR I
gamma I
transcripts I
in O
all O
cell O
lines O
studied O
, O
and O
HMC O
- O
1 O
cells O
were O
the O
only O
line O
lacking O
RXR B
alpha I
. O

Naive O
CD8 O
( O
+ O
) O
Desire O
( O
Des O
) O
( O
+ O
) O
T O
cells O
isolated O
from O
the O
Des O
TCR O
- O
transgenic O
mice O
that O
are O
specific O
for O
the O
H B
- I
2K I
( I
b I
) I
class I
I I
Ag I
were O
transferred O
into O
Alb O
- O
K O
( O
b O
) O
- O
transgenic O
mice O
that O
express O
the O
H B
- I
2K I
( I
b I
) I
Ag I
on O
hepatocytes O
only O
. O

Indeed O
, O
in O
vivo O
primed O
T O
cells O
predominantly O
express O
p50 B
/ I
p50 I
and I
p65 I
/ I
p50 I
dimers I
, O
whereas O
these O
p50 B
- I
containing I
complexes I
are O
barely O
detectable O
in O
tolerant O
T O
cells O
that O
express O
p65 B
- I
and I
c I
- I
Rel I
- I
containing I
complexes I
. O

Indeed O
, O
in O
vivo O
primed O
T O
cells O
predominantly O
express O
p50 B
/ I
p50 I
and I
p65 I
/ I
p50 I
dimers I
, O
whereas O
these O
p50 B
- I
containing I
complexes I
are O
barely O
detectable O
in O
tolerant O
T O
cells O
that O
express O
p65 B
- I
and I
c I
- I
Rel I
- I
containing I
complexes I
. O

Targeting O
Src B
homology I
2 I
domain I
- I
containing I
tyrosine I
phosphatase I
( O
SHP B
- I
1 I
) O
into O
lipid O
rafts O
inhibits O
CD3 B
- O
induced O
T O
cell O
activation O
. O

In O
Jurkat O
T O
cells O
, O
approximately O
5 O
- O
- O
10 O
% O
of O
Src B
homology I
2 I
domain I
- I
containing I
tyrosine I
phosphatase I
( O
SHP B
- I
1 I
) O
is O
constitutively O
associated O
with O
plasma O
membrane O
, O
and O
nearly O
50 O
% O
of O
SHP B
- I
2 I
is O
translocated O
to O
plasma O
membrane O
after O
vanadate O
treatment O
. O

Similar O
to O
transmembrane B
PTP I
, O
CD45 B
, O
the O
membrane O
- O
associated O
populations O
of O
SHP B
- I
1 I
and O
SHP B
- I
2 I
are O
essentially O
excluded O
from O
lipid O
rafts O
, O
where O
other O
signaling B
molecules I
such O
as O
Lck B
, I
linker I
for I
activation I
of I
T I
cells I
, O
and O
CD3 B
zeta I
are O
enriched O
. O

Further O
, O
retroviral O
tagging O
of O
naive O
progenitors O
with O
the O
Th2 B
- I
specific I
transcription I
factor I
GATA I
- I
3 I
provided O
direct O
evidence O
for O
instructive O
differentiation O
, O
and O
no O
evidence O
for O
the O
selective O
outgrowth O
of O
cells O
committed O
to O
either O
the O
Th1 O
or O
Th2 O
fate O
. O

Using O
triple O
transgenic O
mice O
expressing O
a O
TCR B
transgene I
, O
dominant B
negative I
ras I
/ I
Mek I
proteins I
and O
a O
reporter B
gene I
construct I
with O
AP B
- I
1 I
or I
NF I
- I
kappa I
B I
binding I
sites I
, O
we O
showed O
a O
complete O
lack O
of O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
but O
not O
AP B
- I
1 I
in O
DP O
thymocytes O
, O
whereas O
both O
were O
transcriptionally O
active O
in O
mature O
T O
cells O
after O
antigenic O
stimulation O
. O

As O
was O
previously O
reported O
for O
the O
HSV B
- I
1 I
ICP0 I
and I
CMV I
IE1 I
proteins I
, O
Z B
reduces O
the O
amount O
of O
SUMO B
- I
1 I
- I
modified I
PML I
. O

Plasma B
tumor I
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
soluble B
intercellular I
adhesion I
molecule I
- I
1 I
( O
sICAM B
- I
1 I
) O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
( I
MCP I
- I
1 I
) I
, O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
, O
C B
- I
reactive I
protein I
( I
CRP I
) I
, O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
antiinflammatory B
cytokine I
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory B
transcription I
factor I
NFkappaB I
. O

Plasma B
tumor I
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
soluble B
intercellular I
adhesion I
molecule I
- I
1 I
( O
sICAM B
- I
1 I
) O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
( I
MCP I
- I
1 I
) I
, O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
, O
C B
- I
reactive I
protein I
( I
CRP I
) I
, O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
antiinflammatory B
cytokine I
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory B
transcription I
factor I
NFkappaB I
. O

Requirement O
for O
p56 B
LCK I
and I
ZAP I
- I
70 I
protein I
tyrosine I
kinases I
. O

The O
gene O
that O
encodes O
nuclear B
factor I
kappaB I
( I
NF I
- I
kappaB I
) I
essential I
modulator I
( O
or O
NEMO B
, O
also O
known O
as O
IKKgamma B
) O
is O
required O
for O
activation O
of O
the O
transcription B
factor I
NF I
- I
kappaB I
. O

Recent O
observations O
have O
shown O
two O
CCAAT B
/ I
enhancer I
binding I
protein I
( I
C I
/ I
EBP I
) I
binding I
sites I
to O
be O
critically O
important O
for O
efficient O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
replication O
within O
cells O
of O
the O
monocyte O
/ O
macrophage O
lineage O
, O
a O
cell O
type O
likely O
involved O
in O
transport O
of O
the O
virus O
to O
the O
brain O
. O

First O
, O
low O
amounts O
of O
CREB B
- I
1 I
and O
C B
/ I
EBP I
appear O
to O
heterodimerize O
and O
bind O
to O
a O
site O
consisting O
of O
a O
half O
site O
from O
both O
the O
ATF B
/ I
CREB I
and I
C I
/ I
EBP I
binding I
sites I
. O

Sequence O
variation O
at O
both O
C B
/ I
EBP I
and I
ATF I
/ I
CREB I
sites I
affects O
the O
molecular O
interactions O
involved O
in O
mediating O
both O
of O
these O
mechanisms O
. O

The O
inhibitory O
effect O
of O
ASA O
on O
IL O
- O
4 O
transcription O
was O
not O
mediated O
by O
decreased O
nuclear O
expression O
of O
the O
known O
salicylate B
target I
nuclear I
factor I
( I
NF I
) I
- I
kappaB I
and O
was O
accompanied O
by O
reduced O
binding O
of O
an O
inducible O
factor O
to O
an O
IL B
- I
4 I
promoter I
region I
upstream O
of O
, O
but O
not O
overlapping O
, O
the O
NF B
of I
activated I
T I
cells I
- I
and I
NF I
- I
kappaB I
- I
binding I
P1 I
element I
. O

The O
inhibitory O
effect O
of O
ASA O
on O
IL O
- O
4 O
transcription O
was O
not O
mediated O
by O
decreased O
nuclear O
expression O
of O
the O
known O
salicylate B
target I
nuclear I
factor I
( I
NF I
) I
- I
kappaB I
and O
was O
accompanied O
by O
reduced O
binding O
of O
an O
inducible O
factor O
to O
an O
IL B
- I
4 I
promoter I
region I
upstream O
of O
, O
but O
not O
overlapping O
, O
the O
NF B
of I
activated I
T I
cells I
- I
and I
NF I
- I
kappaB I
- I
binding I
P1 I
element I
. O

B6 O
mice O
lacking O
T O
and O
B O
cells O
( O
RAG1 O
- O
/ O
- O
) O
or O
major B
histocompatibility I
complex I
( I
MHC I
) I
class I
II I
antigens I
( O
MHCII O
- O
/ O
- O
) O
, O
and O
B6 O
mice O
treated O
with O
a O
CD4 B
+ I
T I
cell I
- I
depleting I
monoclonal I
antibody I
, O
were O
resistant O
to O
disease O
. O

B6 O
mice O
lacking O
T O
and O
B O
cells O
( O
RAG1 O
- O
/ O
- O
) O
or O
major B
histocompatibility I
complex I
( I
MHC I
) I
class I
II I
antigens I
( O
MHCII O
- O
/ O
- O
) O
, O
and O
B6 O
mice O
treated O
with O
a O
CD4 B
+ I
T I
cell I
- I
depleting I
monoclonal I
antibody I
, O
were O
resistant O
to O
disease O
. O

Acute O
promyelocytic O
leukemia O
( O
APL O
) O
is O
always O
associated O
with O
chromosomal O
translocations O
that O
disrupt O
the O
retinoic B
acid I
receptor I
alpha I
( I
RARalpha I
) I
gene I
. O

Granulocyte O
differentiation O
in O
cells O
derived O
from O
RARalpha O
- O
deficient O
( O
RARalpha O
( O
- O
/ O
- O
) O
) O
mice O
was O
studied O
and O
evaluated O
in O
the O
context O
of O
agonist B
- I
bound I
and I
ligand I
- I
free I
RARalpha I
. O

sIg B
- O
induced O
STAT3 O
activation O
was O
completely O
inhibited O
by O
combining O
IL B
- I
6 I
- I
and I
IL I
- I
10 I
- I
specific I
neutralizing I
antibodies I
, O
or O
by O
adding O
individual O
neutralizing B
antibodies I
to O
B O
cells O
obtained O
from O
lymphokine O
- O
deficient O
animals O
. O

Transcription B
factor I
AP I
- I
4 I
is O
a O
ligand B
for O
immunoglobulin B
- I
kappa I
promoter I
E I
- I
box I
elements I
. O

One O
example O
is O
an O
E B
- I
box I
of O
the O
E47 B
/ I
E12 I
type I
( I
5 I
' I
- I
CAGCTG I
- I
3 I
' I
) I
, O
which O
is O
found O
in O
all O
promoters O
of O
the O
human B
and I
murine I
Ig I
- I
kappa I
gene I
subgroups I
/ I
families I
, O
with O
the O
exception O
of O
subgroups O
II O
and O
VI O
and O
their O
related O
murine B
families I
. O

One O
example O
is O
an O
E B
- I
box I
of O
the O
E47 B
/ I
E12 I
type I
( I
5 I
' I
- I
CAGCTG I
- I
3 I
' I
) I
, O
which O
is O
found O
in O
all O
promoters O
of O
the O
human B
and I
murine I
Ig I
- I
kappa I
gene I
subgroups I
/ I
families I
, O
with O
the O
exception O
of O
subgroups O
II O
and O
VI O
and O
their O
related O
murine B
families I
. O

Based O
on O
these O
data O
, O
and O
the O
conservation O
of O
the O
5 B
' I
- I
CAGCTG I
- I
3 I
' I
motif I
among O
human B
and I
murine I
kappa I
promoters I
, O
we O
propose O
that O
AP B
- I
4 I
is O
the O
major B
ligand I
for O
Ig B
- I
kappa I
promoter I
E I
- I
boxes I
. O

The O
culture O
supernatants O
contained O
increased O
levels O
of O
prostaglandin B
E I
( I
2 I
) I
( I
PGE I
( I
2 I
) I
) I
( O
shown O
to O
favor O
TH2 O
cell O
development O
) O
and O
also O
inhibited O
EBV O
- O
CTL O
effector O
cell O
development O
. O

The O
addition O
of O
BMC O
to O
the O
EBV O
- O
CTL O
generation O
cultures O
increased O
the O
intracellular O
expression O
in O
CD3 O
+ O
cells O
of O
IL B
- I
4 I
, I
- I
5 I
, I
- I
6 I
, I
- I
10 I
, I
and I
- I
13 I
. O

Pax B
- I
5a I
/ I
B I
cell I
- I
specific I
activator I
protein I
and O
an O
alternatively B
spliced I
isoform I
, I
Pax I
- I
5d I
, O
may O
have O
opposing O
functions O
in O
transcriptional O
regulation O
due O
to O
the O
lack O
of O
a O
transactivation B
domain I
in O
Pax B
- I
5d I
. O

BMS O
- O
189453 O
is O
a O
synthetic O
retinoid O
that O
acts O
as O
an O
antagonist O
at O
retinoic B
acid I
receptors I
alpha I
, I
beta I
, I
and I
gamma I
. O

Functional O
blocking O
of O
intercellular B
adhesion I
molecule I
- I
1 I
on O
mesangial O
cells O
with O
rat B
intercellular I
adhesion I
molecule I
- I
1 I
monoclonal I
antibody I
, O
calphostin O
C O
, O
staurosporine O
, O
or O
N O
- O
tosyl O
- O
L O
- O
phenylalanine O
chloromethyl O
ketone O
significantly O
inhibited O
high O
glucose O
- O
or O
high O
mannitol O
- O
induced O
increase O
in O
leukocyte O
adhesion O
( O
p O
< O
< O
0 O
. O
05 O
) O
. O

CD3 B
/ I
CD28 I
- O
promoted O
CREB B
- O
CBP B
interaction O
was O
dependent O
on O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
( I
CaMK I
) I
IV I
in O
addition O
to O
the O
previously O
identified O
extracellular O
signal O
- O
regulated O
kinase O
pathway O
. O

The O
NF B
- I
kappa I
B I
family I
of I
transcription I
factors I
is O
an O
important O
regulator O
of O
genes O
expressed O
during O
inflammatory O
responses O
, O
immunoglobulin O
( O
Ig O
) O
class O
switching O
, O
cellular O
differentiation O
, O
and O
apoptosis O
. O

We O
investigated O
the O
expression O
of O
active B
NF I
- I
kappa I
B I
p65 I
( I
Rel I
A I
) I
in O
cases O
of O
mycosis O
fungoides O
( O
MF O
) O
and O
the O
effect O
of O
chemical O
inhibitors O
of O
NF B
- I
kappa I
B I
on O
apoptosis O
in O
cutaneous O
T O
cell O
lymphoma O
( O
CTCL O
) O
cell O
lines O
. O

These O
data O
show O
that O
the O
active O
form O
of O
NF B
- I
kappa I
B I
p65 I
( I
Rel I
A I
) I
is O
commonly O
expressed O
in O
neoplastic O
T O
lymphocytes O
in O
patients O
with O
MF O
. O

Tax B
activates O
the O
expression O
of O
viral B
and I
cellular I
genes I
through O
two O
different O
enhancers O
: O
a O
cAMP B
- I
responsive I
( I
CRE I
) I
- I
like I
element I
and O
a O
kappaB B
element I
. O

Incubation O
of O
SF O
with O
neutralizing B
antibodies I
against O
tumor B
necrosis I
factor I
- I
alpha I
( I
TNF I
- I
alpha I
) I
, O
but O
not O
antibodies B
against O
interleukin B
6 I
( I
IL I
- I
6 I
) I
, O
significantly O
reduced O
the O
induction O
of O
p65 O
/ O
p50 O
binding O
activity O
in O
SF O
from O
subjects O
with O
RA O
and O
OA O
. O

The O
research O
described O
herein O
evaluates O
the O
expression O
and O
functional O
significance O
of O
peroxisome B
proliferator I
activator I
receptor I
- I
gamma I
( I
PPAR I
- I
gamma I
) I
on O
B O
- O
lineage O
cells O
. O

However O
, O
we O
found O
that O
the O
Bcl B
- I
2 I
- I
family I
protein I
Mcl I
- I
1 I
was O
significantly O
reduced O
by O
AG O
- O
490 O
treatment O
. O

Transcription B
factor I
activating I
transcription I
factor I
( I
ATF I
) I
- I
2 I
is O
activated O
by O
inflammatory O
signals O
transduced O
by O
the O
JNK O
and O
p38 O
MAP O
kinase O
pathways O
. O

Activity O
of O
the O
distal B
region I
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
- O
1 O
) O
long B
terminal I
repeat I
( O
LTR B
) O
, O
which O
contains O
binding B
sites I
for O
the O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
, O
is O
integral O
for O
HIV O
- O
1 O
replication O
. O

The O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
play O
a O
critical O
role O
in O
the O
activity O
of O
the O
HIV B
- I
1 I
LTR I
distal I
enhancer I
region I
, O
as O
indicated O
by O
the O
potent O
dominant O
negative O
effect O
of O
a O
mutant B
Ets I
- I
1 I
lacking I
trans I
- I
activation I
domains I
on O
the O
transcriptional O
activity O
of O
the O
LTR B
. O

The O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
play O
a O
critical O
role O
in O
the O
activity O
of O
the O
HIV B
- I
1 I
LTR I
distal I
enhancer I
region I
, O
as O
indicated O
by O
the O
potent O
dominant O
negative O
effect O
of O
a O
mutant B
Ets I
- I
1 I
lacking I
trans I
- I
activation I
domains I
on O
the O
transcriptional O
activity O
of O
the O
LTR B
. O

To O
determine O
the O
biological O
relevance O
of O
the O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
in O
HIV O
- O
1 O
replication O
, O
we O
examined O
the O
effect O
of O
expression O
of O
the O
dominant O
- O
negative O
mutant O
of O
Ets B
- I
1 I
( O
dnEts B
- I
1 I
) O
on O
HIV O
- O
1 O
infection O
of O
T O
cells O
. O

This O
finding O
indicates O
that O
formation O
of O
a O
transcriptionaly B
active I
USF I
- I
1 I
/ I
Ets I
- I
1 I
complex I
is O
important O
in O
the O
productive O
infection O
of O
cells O
by O
HIV O
- O
1 O
, O
and O
suggests O
that O
inhibition O
of O
the O
interaction O
between O
USF B
- I
1 I
and O
Ets B
- I
1 I
with O
the O
HIV B
- I
1 I
LTR I
may O
provide O
a O
new O
target O
for O
anti O
- O
HIV O
- O
1 O
gene O
therapy O
. O

Human O
eosinophils O
constitutively O
express O
nuclear B
factor I
of I
activated I
T I
cells I
p I
and I
c I
. O

By O
Northern O
analysis O
, O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
- I
2 I
mRNA I
in O
BAL O
cells O
increased O
markedly O
1 O
h O
after O
NaVO3 O
instillation O
and O
reduced O
a O
little O
bit O
at O
4 O
h O
, O
whereas O
MIP B
- I
1alpha I
mRNA I
in O
BAL O
cells O
was O
expressed O
relatively O
high O
1 O
h O
after O
NaVO3 O
instillation O
, O
although O
a O
basal O
expression O
was O
detected O
in O
control O
group O
, O
and O
returned O
rapidly O
nearly O
to O
control O
level O
at O
4 O
h O
. O

The O
physical O
association O
of O
protein B
kinase I
C I
theta I
with O
a O
lipid O
raft O
- O
associated O
inhibitor O
of O
kappa B
B I
factor I
kinase I
( I
IKK I
) I
complex I
plays O
a O
role O
in O
the O
activation O
of O
the O
NF O
- O
kappa O
B O
cascade O
by O
TCR B
and O
CD28 B
. O

Bone O
resorption O
is O
regulated O
by O
the O
immune O
system O
, O
where O
T O
- O
cell O
expression O
of O
RANKL B
( O
receptor B
activator I
of I
nuclear I
factor I
( I
NF I
) I
- I
kappaB I
ligand I
) O
, O
a O
member O
of O
the O
tumour B
- I
necrosis I
factor I
family I
that O
is O
essential O
for O
osteoclastogenesis O
, O
may O
contribute O
to O
pathological O
conditions O
, O
such O
as O
autoimmune O
arthritis O
. O

IFN B
- I
gamma I
induces O
rapid O
degradation O
of O
the O
RANK B
adapter I
protein I
, O
TRAF6 B
( O
tumour B
necrosis I
factor I
receptor I
- I
associated I
factor I
6 I
) O
, O
which O
results O
in O
strong O
inhibition O
of O
the O
RANKL B
- O
induced O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
JNK B
. O

Investigating O
the O
intracellular O
signaling O
pathways O
induced O
by O
SDF B
- I
1 I
and O
TPO B
revealed O
some O
overlapping O
patterns O
of O
protein O
phosphorylation O
/ O
activation O
( O
mitogen B
- I
activated I
protein I
kinase I
[ I
MAPK I
] I
p42 I
/ I
44 I
, O
MAPK B
p38 I
, O
and O
AKT B
[ I
protein I
kinase I
B I
] I
) O
and O
some O
that O
were O
distinct O
for O
TPO B
( O
eg O
, O
JAK B
- I
STAT I
) O
and O
for O
SDF B
- I
1 I
( O
eg O
, O
NF B
- I
kappa I
B I
) O
. O

We O
have O
identified O
a O
novel O
Kruppel B
- I
type I
zinc I
finger I
( I
ZF I
) I
gene I
, O
SKAT B
- I
2 I
, O
which O
is O
selectively O
expressed O
by O
murine O
Th2 O
cells O
. O

In O
transient O
transfection O
experiments O
in O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
/ O
ionomycin O
- O
stimulated O
EL4 O
cells O
, O
SKAT B
- I
2 I
was O
found O
to O
up O
- O
regulate O
the O
activity O
of O
the O
IL B
- I
4 I
but I
not I
the I
IL I
- I
5 I
promoter I
, O
contrasting O
with O
the O
ability O
of O
GATA B
- I
3 I
to O
activate O
both O
promoters B
. O

Reticulocyte O
lysate O
contains O
a O
chaperone O
system O
that O
assembles O
glucocorticoid B
receptor I
( I
GR I
) I
. I
hsp90 I
heterocomplexes I
. O

FD O
/ O
deltaRaf O
- O
1 O
: O
ER O
cells O
growing O
in O
response O
to O
Raf O
activation O
displayed O
decreased O
levels O
of O
the O
Mac B
- I
2 I
and I
Mac I
- I
3 I
molecules I
on O
their O
cell O
surface O
. O

Characterization O
of O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
dependent O
on O
the O
human B
IL I
- I
13 I
receptor I
alpha I
chain I
1 I
: O
redundancy O
of O
requirement O
of O
tyrosine O
residue O
for O
STAT3 O
activation O
. O

In O
contrast O
, O
AG O
- O
490 O
had O
no O
effect O
on O
DNA O
binding O
by O
p50 B
/ I
p65 I
components I
of O
NF B
- I
kappaB I
, O
a O
transcription B
factor I
activated O
by O
the O
HTLV B
- I
1 I
- I
encoded I
phosphoprotein I
, I
Tax I
. O

In O
contrast O
, O
AG O
- O
490 O
had O
no O
effect O
on O
DNA O
binding O
by O
p50 B
/ I
p65 I
components I
of O
NF B
- I
kappaB I
, O
a O
transcription B
factor I
activated O
by O
the O
HTLV B
- I
1 I
- I
encoded I
phosphoprotein I
, I
Tax I
. O

The O
Epstein B
- I
Barr I
virus I
promoter I
initiating O
B O
- O
cell O
transformation O
is O
activated O
by O
RFX B
proteins I
and O
the O
B B
- I
cell I
- I
specific I
activator I
protein I
BSAP I
/ I
Pax5 I
. O

Here O
we O
show O
that O
site B
C I
binds O
members O
of O
the O
ubiquitously O
expressed O
RFX B
family I
of I
proteins I
, O
notably O
RFX1 B
, O
RFX3 B
, O
and O
the O
associated O
factor O
MIBP1 B
, O
whereas O
sites B
B I
and I
D I
both O
bind O
the O
B B
- I
cell I
- I
specific I
activator I
protein I
BSAP I
/ I
Pax5 I
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
role O
of O
the O
proteasome B
for O
ligand O
- O
dependent O
endocytosis O
and O
degradation O
of O
the O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
- I
interleukin I
- I
2 I
receptor I
( I
IL I
- I
2R I
) I
complex I
. O

Transient O
expression O
of O
actively O
mutated O
Fyn B
, O
having O
Phe O
- O
528 O
instead O
of O
Tyr O
- O
528 O
or O
Thr O
- O
338 O
instead O
of O
Ile O
- O
338 O
, O
in O
Jurkat O
T O
- O
cells O
stimulated B
the I
serum I
response I
element I
( O
SRE B
) O
, O
12 B
- I
O I
- I
tetradecanoyl I
- I
phorbol I
- I
13 I
- I
acetate I
response I
element I
, O
cyclic B
AMP I
response I
element I
, O
and O
c B
- I
fos I
promoter I
. O

Interestingly O
, O
a O
mutant B
Fyn I
, O
which O
has O
deletions O
within O
the O
SH2 B
region I
and O
so O
is O
able O
to O
transform O
chicken O
embryo O
fibroblasts O
, O
did O
not O
stimulate O
either O
the O
c B
- I
fos I
or I
IL I
- I
2 I
promoter I
, O
suggesting O
the O
importance O
of O
this O
region O
in O
T O
- O
cell O
signaling O
. O

As O
with O
the O
prototypical O
NF B
- I
kappa I
B I
p50 I
- I
p65 I
heterodimer I
, O
this O
novel O
p65 B
homodimeric I
form I
of O
NF B
- I
kappa I
B I
is O
functionally O
sequestered O
in O
the O
cytoplasm O
but O
rapidly O
appears O
in O
the O
nuclear O
compartment O
following O
cellular O
stimulation O
. O

Furthermore O
, O
addition O
of O
sodium O
butyrate O
or O
1 O
alpha O
, O
25 O
- O
dihydroxyvitamin O
D3 O
to O
HL O
- O
60 O
cells O
induced O
the O
expression O
of O
c B
- I
fos I
, I
c I
- I
jun I
, I
jun I
B I
and I
jun I
D I
proto I
- I
oncogenes I
. O

' B
Activation I
- I
labile I
' I
glucocorticoid I
- I
receptor I
complexes I
of O
a O
steroid O
- O
resistant O
variant O
of O
CEM O
- O
C7 O
human O
lymphoid O
cells O
. O

The O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
promoter I
cis I
- I
acting I
element I
CLE0 B
mediates O
induction O
signals O
in O
T O
cells O
and O
is O
recognized O
by O
factors O
related O
to O
AP1 B
and O
NFAT B
. O

Expression O
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
gene I
in O
T O
cells O
is O
activated O
by O
the O
combination O
of O
phorbol O
ester O
( O
phorbol O
myristate O
acetate O
) O
and O
calcium O
ionophore O
( O
A23187 O
) O
, O
which O
mimic O
antigen O
stimulation O
through O
the O
T B
- I
cell I
receptor I
. O

The O
presence O
of O
CLE0 B
- I
like I
elements I
in O
the O
promoters B
of O
interleukin B
- I
3 I
( I
IL I
- I
3 I
) I
, I
IL I
- I
4 I
, I
IL I
- I
5 I
, I
GM I
- I
CSF I
, I
and I
NFAT I
sites I
in O
the O
IL B
- I
2 I
promoter I
suggests O
that O
the O
factors O
we O
detected O
, O
or O
related O
factors O
that O
recognize O
these O
sites O
, O
may O
account O
for O
the O
coordinate O
induction O
of O
these O
genes O
during O
T O
- O
cell O
activation O
. O

Identification O
and O
characterization O
of O
an O
Alu B
- I
containing I
, I
T I
- I
cell I
- I
specific I
enhancer I
located O
in O
the O
last O
intron B
of O
the O
human B
CD8 I
alpha I
gene I
. O

DNA O
sequence O
analysis O
of O
the O
minimal B
enhancer I
revealed O
a O
striking O
cluster O
of O
consensus B
binding I
sites I
for O
Ets B
- I
1 I
, I
TCF I
- I
1 I
, I
CRE I
, I
GATA I
- I
3 I
, I
LyF I
- I
1 I
, I
and I
bHLH I
proteins I
which O
were O
verified O
by O
electrophoretic O
mobility O
shift O
assays O
. O

In O
addition O
, O
the O
5 B
' I
end I
of O
the O
enhancer B
was O
composed O
of O
an O
Alu O
repeat O
which O
contained O
the O
GATA B
- I
3 I
, I
bHLH I
, I
and I
LyF I
- I
1 I
binding I
sites I
. O

Site O
- O
directed O
mutation O
of O
the O
Ets B
- I
1 I
and I
GATA I
- I
3 I
sites I
dramatically O
reduced O
enhancer O
activity O
. O

Molecular O
regulation O
of O
the O
human B
IL I
- I
3 I
gene I
: O
inducible O
T O
cell O
- O
restricted O
expression O
requires O
intact O
AP B
- I
1 I
and I
Elf I
- I
1 I
nuclear I
protein I
binding I
sites I
. O

Interleukin B
3 I
( O
IL B
- I
3 I
) O
is O
a O
hematopoietic B
stem I
- I
cell I
growth I
and I
differentiation I
factor I
that O
is O
expressed O
solely O
in O
activated O
T O
and O
NK O
cells O
. O

A O
series O
of O
transient O
transfections O
performed O
with O
human B
IL I
- I
3 I
- I
chloramphenicol I
acetyltransferase I
( I
CAT I
) I
reporter I
plasmids I
in O
T O
and O
non O
- O
T O
cells O
revealed O
that O
a O
plasmid B
containing O
319 O
bp O
of O
5 B
' I
flanking I
sequences I
was O
active O
exclusively O
in O
T O
cells O
. O

DNaseI B
footprint O
and O
electrophoretic O
mobility O
shift O
assay O
analyses O
performed O
with O
MLA O
- O
144 O
T O
cell O
nuclear O
extracts O
demonstrated O
that O
this O
49 B
- I
bp I
region I
contains O
a O
nuclear B
protein I
binding I
region I
that O
includes O
consensus B
AP I
- I
1 I
and I
Elf I
- I
1 I
binding I
sites I
. O

In O
addition O
, O
extracts O
prepared O
from O
purified O
human O
T O
cells O
contained O
proteins O
that O
bound O
to O
synthetic O
oligonucleotides O
corresponding O
to O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
binding I
sites I
. O

We O
conclude O
that O
expression O
of O
the O
human B
IL I
- I
3 I
gene I
requires O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
binding I
sites I
; O
however O
, O
unlike O
other O
previously O
characterized O
cytokine B
genes I
such O
as O
IL B
- I
2 I
, O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
factors I
can O
bind O
independently O
in O
the O
IL B
- I
3 I
gene I
. O

We O
conclude O
that O
expression O
of O
the O
human B
IL I
- I
3 I
gene I
requires O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
binding I
sites I
; O
however O
, O
unlike O
other O
previously O
characterized O
cytokine B
genes I
such O
as O
IL B
- I
2 I
, O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
factors I
can O
bind O
independently O
in O
the O
IL B
- I
3 I
gene I
. O

The O
human B
TNF I
promoter I
contains O
four O
potential O
nuclear B
factor I
- I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
- I
binding I
sites I
, O
with O
the O
strongest O
binding O
seen O
for O
the O
- O
605 O
motif O
. O

These O
regions O
are O
designated O
YI B
( O
amino B
acids I
[ I
aa I
] I
1 I
to I
25 I
) O
, O
YII B
( O
aa B
51 I
to I
102 I
) O
, O
and O
YIII B
( O
aa B
228 I
to I
245 I
) O
. O

Functional O
interaction O
of O
the O
v B
- I
Rel I
and I
c I
- I
Rel I
oncoproteins I
with O
the O
TATA B
- I
binding I
protein I
and O
association O
with O
transcription B
factor I
IIB I
. O

We O
have O
investigated O
the O
ability O
of O
the O
v B
- I
Rel I
and I
c I
- I
Rel I
oncoproteins I
to O
interact O
with O
components O
of O
the O
basal O
transcription O
machinery O
. O

Combined O
with O
the O
observation O
that O
the O
mouse B
c I
- I
Rel I
and I
human I
RelA I
proteins I
also O
interact O
with O
TBP B
and O
TFIIB B
in O
vitro O
, O
these O
results O
suggest O
that O
association O
with O
basal B
transcription I
factors I
is O
important O
for O
the O
transcriptional O
activities O
of O
Rel B
family I
proteins I
. O

Calcium O
signals O
are O
important O
for O
NFAT O
induction O
, O
and O
recent O
studies O
have O
identified O
calcineurin B
, O
a O
calcium B
- I
calmodulin I
dependent I
serine I
- I
threonine I
phosphatase I
, O
as O
a O
prominent O
component O
of O
the O
calcium O
signaling O
pathway O
in O
T O
cells O
. O

We O
then O
examined O
the O
ability O
of O
the O
affinity O
gel O
to O
recognize O
cytosolic B
[ I
3H I
] I
triamcinolone I
acetonide I
- I
receptor I
complexes I
from O
the O
corticoid O
- O
sensitive O
( O
CS O
) O
and O
- O
resistant O
strains O
of O
mouse O
lymphoma O
P1798 O
, O
from O
CS O
lymphocytes O
of O
patients O
with O
chronic O
lymphatic O
leukemia O
, O
and O
from O
a O
CS O
clone O
of O
human O
leukemic O
lymphoblasts O
in O
tissue O
culture O
( O
CH6 O
) O
. O

Whereas O
the O
immunoaffinity O
column O
retained O
70 O
to O
84 O
% O
of O
the O
58 O
- O
to O
62 O
- O
A O
( O
Stokes O
radius O
) O
[ B
3H I
] I
triamcinolone I
acetonide I
- I
receptor I
complexes I
characteristic O
of O
the O
CS O
mouse O
and O
human O
lymphocytes O
, O
it O
failed O
to O
recognize O
the O
27 O
- O
to O
28 O
- O
A O
( O
Stokes O
radius O
) O
glucocorticoid B
receptor I
present O
in O
corticoid O
- O
resistant O
mouse O
lymphoma O
P1798 O
cells O
. O

The O
role O
of O
NF B
- I
kappa I
B1 I
( I
p50 I
/ I
p105 I
) I
gene I
expression O
in O
activation O
of O
human O
blood O
T O
- O
lymphocytes O
via O
CD2 B
and I
CD28 I
adhesion I
molecules I
. O

This O
potent O
activation O
does O
not O
require O
accessory O
cells O
, O
such O
as O
monocytes O
, O
but O
depends O
on O
persistent O
interleukin B
2 I
( O
IL B
- I
2 I
) O
secretion O
and O
receptivity O
, O
which O
is O
associated O
with O
high O
and O
prolonged O
expression O
of O
the O
inducible O
CD25 B
/ I
IL I
- I
2 I
receptor I
alpha I
( I
IL I
- I
2R I
alpha I
) I
chain I
gene I
. O

The O
transcription B
factor I
NF I
- I
kappa I
B I
participates O
in O
the O
regulation O
of O
both O
IL B
- I
2 I
and I
IL I
- I
2R I
alpha I
genes I
, O
as O
well O
as O
multiple B
cellular I
genes I
involved O
in O
T O
- O
cell O
proliferation O
. O

H2O2 O
was O
found O
to O
stimulate O
Ins B
- I
1 I
, I
4 I
, I
5 I
- I
P3 I
production O
in O
a O
tyrosine O
kinase O
- O
dependent O
manner O
and O
to O
induce O
calcium O
signals O
that O
were O
greatly O
augmented O
by O
vanadate O
. O

Influence O
of O
sex B
hormone I
binding I
globulin I
and O
serum B
albumin I
on O
the O
conversion O
of O
androstenedione O
to O
testosterone O
by O
human O
erythrocytes O
. O

A O
reliable O
procedure O
is O
described O
for O
isolating O
3H B
- I
triamcinolone I
acetonide I
( I
3H I
- I
TA I
) I
receptor I
complexes I
from O
purified O
chronic O
lymphatic O
leukemia O
( O
CLL O
) O
lymphocyte O
nuclei O
, O
based O
on O
the O
use O
of O
carbobenzoxy O
- O
L O
- O
phenylalanine O
( O
CBZ O
- O
L O
- O
phe O
) O
to O
prevent O
breakdown O
of O
hormone B
- I
receptor I
complexes I
during O
extraction O
of O
nuclei O
with O
0 O
. O
6M O
KCl O
. O

We O
show O
here O
that O
the O
immediate B
upstream I
region I
( O
from O
position O
- O
12 O
to O
- O
270 O
) O
of O
the O
murine B
interleukin I
4 I
( I
Il I
- I
4 I
) I
gene I
harbors O
a O
strong O
cell O
- O
type O
specific O
transcriptional B
enhancer I
. O

They O
contain O
the O
motif O
GGAAA O
and O
are O
recognized O
by O
the O
inducible B
and I
cyclosporin I
A I
- I
sensitive I
transcription I
factor I
NFAT I
- I
1 I
. O

Cell O
surface O
expression O
of O
IL B
- I
2R I
alpha I
- I
and I
beta I
- I
chains I
as O
determined O
by O
immunofluorescence O
analysis O
was O
not O
affected O
by O
Dex O
. O

The O
70 B
- I
kDa I
protein I
corresponds O
to O
the O
NF B
- I
kappa I
B I
RelA I
( I
p65 I
) I
subunit I
, O
which O
is O
activated O
in O
response O
to O
an O
acute O
paramyxovirus O
infection O
or O
a O
chronic O
HIV O
- O
1 O
infection O
. O

DNA O
binding O
of O
the O
90 B
- I
to I
100 I
- I
kDa I
proteins I
was O
not O
inhibited O
by O
recombinant B
I I
kappa I
B I
alpha I
/ I
MAD I
- I
3 I
and O
was O
resistant O
to O
tryptic O
digestion O
, O
suggesting O
that O
these O
proteins O
may O
not O
be O
NF B
- I
kappa I
B I
related I
. O

Transient O
cotransfection O
experiments O
demonstrated O
that O
RelA O
and O
NFKB1 O
expression O
maximally O
stimulated O
HIV B
- I
1 I
LTR I
- I
and I
NF I
- I
kappa I
B I
- I
dependent I
reporter I
genes I
; O
differences O
in O
NF O
- O
kappa O
B O
- O
like O
binding O
activity O
were O
also O
reflected O
in O
higher O
constitutive O
levels O
of O
NF O
- O
kappa O
B O
- O
regulated O
gene O
expression O
in O
HIV O
- O
1 O
- O
infected O
myeloid O
cells O
. O

